Akros SCHK HK-U.S. Biotech Index

Q2 2026 earnings release on August 6, 2026, following a Q1 beat; medium importance estimated based on expected >=5% price impact, scheduled.

Q2 2026 earnings release and conference call on 2026-08-05 scheduled. Low importance estimated as it is a routine scheduled announcement.

Merck & Co. is scheduled to release its Q2 2026 financial results on 2026-08-04. Earnings releases are high-impact events that can significantly influence stock price, estimated to have a high market impact (≥10%) scheduled.

Amgen Q2 2026 earnings conference call on August 4, 2026, scheduled; medium impact estimated from updated financial outlook and guidance.

Pfizer is scheduled to release its Q2 2026 earnings results before the market opens on August 4, 2026. Analysts forecast EPS of $0.68 and revenue of $14.45 billion, which is forecasted. Medium importance is estimated as earnings reports typically drive significant price volatility. The event is scheduled.

AbbVie's second-quarter 2026 financial results are scheduled to be announced on July 31, 2026, before the market opens; a 5% price impact is estimated based on historical earnings volatility, scheduled.

Q2 2026 earnings release scheduled. Analysts forecast EPS of $1.61. Expected to have a moderate impact as a key financial update; estimated.

FDA hearing deadline to address the proposal to withdraw marketing approval for Tavneos on July 29, 2026, scheduled; high impact estimated due to potential market exit and revenue loss.

Abbott is scheduled to report its Q2 2026 financial results on July 16, 2026, before the market opens. Options market data implies a potential 4.5% stock price move following the release. This is a future event, so importance is an estimate based on historical volatility. scheduled

Johnson & Johnson is scheduled to release its Q2 2026 earnings results on July 15, 2026. Analysts forecast earnings of $2.86 per share on revenue of $25.06 billion. Medium importance is estimated based on historical price volatility following quarterly earnings reports, scheduled.

U.S. FDA accepted a New Drug Application for mezigdomide on 2026-07-13. Target action date (PDUFA) is May 13, 2027. This milestone is expected to have a moderate impact; expected.

The U.S. FDA approved KEYTRUDA in combination with Padcev for muscle-invasive bladder cancer on 2026-07-10. This major indication approval is estimated to have a medium market impact (≥5%) due to significant revenue potential expected.

The U.S. FDA approved the combination of Pfizer's PADCEV and Merck's Keytruda for muscle-invasive bladder cancer on July 10, 2026. Medium importance is estimated as this is the first platinum-free regimen for this indication, significantly expanding the market.